Nanopharmacology in translational hematology and oncology

Ciprian Tomuleasa,1,2,* Cornelia Braicu,1,* Alexandra Irimie,3 Lucian Craciun,1 Ioana Berindan-Neagoe1,4,51Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 2Department of Hematology, Ion Chiricuta Cancer Center, 3D...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tomuleasa C, Braicu C, Irimie A, Craciun L, Berindan-Neagoe I
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/8b29a25463494f839e77c0541e3570c6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8b29a25463494f839e77c0541e3570c6
record_format	dspace
spelling	oai:doaj.org-article:8b29a25463494f839e77c0541e3570c62021-12-02T02:42:20ZNanopharmacology in translational hematology and oncology1178-2013https://doaj.org/article/8b29a25463494f839e77c0541e3570c62014-07-01T00:00:00Zhttp://www.dovepress.com/nanopharmacology-in-translational-hematology-and-oncology-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013 Ciprian Tomuleasa,1,2,* Cornelia Braicu,1,* Alexandra Irimie,3 Lucian Craciun,1 Ioana Berindan-Neagoe1,4,51Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 2Department of Hematology, Ion Chiricuta Cancer Center, 3Department of Prosthetic Dentistry and Dental Materials, 4Department of Immunology, Iuliu Hatieganu University of Medicine and Pharmacy, 5Department of Functional Genomics and Experimental Pathology, the Oncological Institute “Prof Dr Ion Chiricuta”, Cluj-Napoca, Romania*These authors contributed equally to this workAbstract: Nanoparticles have displayed considerable promise for safely delivering therapeutic agents with miscellaneous therapeutic properties. Current progress in nanotechnology has put forward, in the last few years, several therapeutic strategies that could be integrated into clinical use by using constructs for molecular diagnosis, disease detection, cytostatic drug delivery, and nanoscale immunotherapy. In the hope of bringing the concept of nanopharmacology toward a viable and feasible clinical reality in a cancer center, the present report attempts to present the grounds for the use of cell-free nanoscale structures for molecular therapy in experimental hematology and oncology.Keywords: hematological malignancies, nanoparticles, translational medicineTomuleasa CBraicu CIrimie ACraciun LBerindan-Neagoe IDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2014, Iss Issue 1, Pp 3465-3479 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Tomuleasa C Braicu C Irimie A Craciun L Berindan-Neagoe I Nanopharmacology in translational hematology and oncology
description	Ciprian Tomuleasa,1,2,* Cornelia Braicu,1,* Alexandra Irimie,3 Lucian Craciun,1 Ioana Berindan-Neagoe1,4,51Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 2Department of Hematology, Ion Chiricuta Cancer Center, 3Department of Prosthetic Dentistry and Dental Materials, 4Department of Immunology, Iuliu Hatieganu University of Medicine and Pharmacy, 5Department of Functional Genomics and Experimental Pathology, the Oncological Institute “Prof Dr Ion Chiricuta”, Cluj-Napoca, Romania*These authors contributed equally to this workAbstract: Nanoparticles have displayed considerable promise for safely delivering therapeutic agents with miscellaneous therapeutic properties. Current progress in nanotechnology has put forward, in the last few years, several therapeutic strategies that could be integrated into clinical use by using constructs for molecular diagnosis, disease detection, cytostatic drug delivery, and nanoscale immunotherapy. In the hope of bringing the concept of nanopharmacology toward a viable and feasible clinical reality in a cancer center, the present report attempts to present the grounds for the use of cell-free nanoscale structures for molecular therapy in experimental hematology and oncology.Keywords: hematological malignancies, nanoparticles, translational medicine
format	article
author	Tomuleasa C Braicu C Irimie A Craciun L Berindan-Neagoe I
author_facet	Tomuleasa C Braicu C Irimie A Craciun L Berindan-Neagoe I
author_sort	Tomuleasa C
title	Nanopharmacology in translational hematology and oncology
title_short	Nanopharmacology in translational hematology and oncology
title_full	Nanopharmacology in translational hematology and oncology
title_fullStr	Nanopharmacology in translational hematology and oncology
title_full_unstemmed	Nanopharmacology in translational hematology and oncology
title_sort	nanopharmacology in translational hematology and oncology
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/8b29a25463494f839e77c0541e3570c6
work_keys_str_mv	AT tomuleasac nanopharmacologyintranslationalhematologyandoncology AT braicuc nanopharmacologyintranslationalhematologyandoncology AT irimiea nanopharmacologyintranslationalhematologyandoncology AT craciunl nanopharmacologyintranslationalhematologyandoncology AT berindanneagoei nanopharmacologyintranslationalhematologyandoncology
_version_	1718402232637980672

Nanopharmacology in translational hematology and oncology

Ejemplares similares